vs
Side-by-side financial comparison of AIRO Group Holdings, Inc. (AIRO) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
AIRO Group Holdings, Inc. is the larger business by last-quarter revenue ($6.3M vs $5.5M, roughly 1.1× Taysha Gene Therapies, Inc.). AIRO Group Holdings, Inc. runs the higher net margin — -126.7% vs -507.8%, a 381.1% gap on every dollar of revenue.
Airo Aviation FZ-LLC was an Emirati aircraft manufacturer based in the Ras Al Khaimah Free Trade Zone. The company specialized in the manufacture of ultralight aircraft in the form of ready-to-fly aircraft for the European Fédération Aéronautique Internationale microlight category.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
AIRO vs TSHA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.3M | $5.5M |
| Net Profit | $-8.0M | $-27.9M |
| Gross Margin | 44.4% | — |
| Operating Margin | -190.7% | -516.0% |
| Net Margin | -126.7% | -507.8% |
| Revenue YoY | — | 171.3% |
| Net Profit YoY | — | -48.3% |
| EPS (diluted) | $-0.28 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.5M | ||
| Q3 25 | $6.3M | $0 | ||
| Q2 25 | $24.6M | $2.0M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $3.4M |
| Q4 25 | — | $-27.9M | ||
| Q3 25 | $-8.0M | $-32.7M | ||
| Q2 25 | $5.9M | $-26.9M | ||
| Q1 25 | — | $-21.5M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-25.5M | ||
| Q2 24 | — | $-20.9M | ||
| Q1 24 | — | $-24.1M |
| Q4 25 | — | — | ||
| Q3 25 | 44.4% | — | ||
| Q2 25 | 61.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -516.0% | ||
| Q3 25 | -190.7% | — | ||
| Q2 25 | -80.2% | -1347.1% | ||
| Q1 25 | — | -930.5% | ||
| Q4 24 | — | -985.8% | ||
| Q3 24 | — | -1448.4% | ||
| Q2 24 | — | -1915.4% | ||
| Q1 24 | — | -713.3% |
| Q4 25 | — | -507.8% | ||
| Q3 25 | -126.7% | — | ||
| Q2 25 | 23.9% | -1353.6% | ||
| Q1 25 | — | -935.2% | ||
| Q4 24 | — | -929.0% | ||
| Q3 24 | — | -1427.5% | ||
| Q2 24 | — | -1882.0% | ||
| Q1 24 | — | -705.4% |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.28 | $-0.09 | ||
| Q2 25 | $0.30 | $-0.09 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $319.8M |
| Total DebtLower is stronger | $5.1M | — |
| Stockholders' EquityBook value | $739.5M | $246.9M |
| Total Assets | $774.6M | $343.3M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $319.8M | ||
| Q3 25 | — | $297.3M | ||
| Q2 25 | — | $312.8M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | — | $139.0M | ||
| Q3 24 | — | $157.7M | ||
| Q2 24 | — | $172.7M | ||
| Q1 24 | — | $124.0M |
| Q4 25 | — | — | ||
| Q3 25 | $5.1M | — | ||
| Q2 25 | $8.9M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $246.9M | ||
| Q3 25 | $739.5M | $219.0M | ||
| Q2 25 | $679.6M | $248.7M | ||
| Q1 25 | — | $55.1M | ||
| Q4 24 | — | $71.5M | ||
| Q3 24 | — | $88.8M | ||
| Q2 24 | — | $108.9M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | $343.3M | ||
| Q3 25 | $774.6M | $316.6M | ||
| Q2 25 | $747.8M | $333.3M | ||
| Q1 25 | — | $138.4M | ||
| Q4 24 | — | $160.4M | ||
| Q3 24 | — | $180.2M | ||
| Q2 24 | — | $200.4M | ||
| Q1 24 | — | $153.0M |
| Q4 25 | — | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $-26.7M |
| Free Cash FlowOCF − Capex | $-6.7M | — |
| FCF MarginFCF / Revenue | -106.7% | — |
| Capex IntensityCapex / Revenue | 15.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-26.7M | ||
| Q3 25 | $-5.8M | $-24.2M | ||
| Q2 25 | $-30.8M | $-20.2M | ||
| Q1 25 | — | $-22.0M | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.5M | ||
| Q1 24 | — | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-6.7M | $-24.3M | ||
| Q2 25 | $-31.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | -106.7% | — | ||
| Q2 25 | -129.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -5.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIRO
| Transferred At Point In Time | $4.5M | 71% |
| Transferred Over Time | $1.8M | 29% |
TSHA
Segment breakdown not available.
